Sweet syndrome in patients with and without malignancy: A retrospective analysis of 83 patients from a tertiary academic referral center

Nelson, Caroline A.; Noe, Megan H.; McMahon, Christine M.; Gowda, Asha; Wu, Benedict; Ashchyan, Hovik J.; Perl, Alexander E.; James, William D.; Micheletti, Robert G.; Rosenbach, Misha

doi:10.1016/j.jaad.2017.09.013

Cited by 77 publications

(84 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A retrospective case series of 83 Sweet syndrome patients with and without malignancy corroborated that leukopenia, anemia, and thrombocytopenia were associated with malignancy (14). Our study also revealed that hematologic malignancy was associated with lower hemoglobin and platelet levels.…”

Section: Discussionsupporting

confidence: 80%

Insights Into the Characteristics of Sweet Syndrome in Patients With and Without Hematologic Malignancy

Zheng

Tang

et al. 2020

Front. Med.

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 80%

Insights Into the Characteristics of Sweet Syndrome in Patients With and Without Hematologic Malignancy

Zheng

Tang

et al. 2020

Front. Med.

View full text Add to dashboard Cite

“…MDS was the second most common causative malignancy after acute myeloblastic leukemia, further highlighting the necessity of excluding the possibility of MDSassociated neutrophilic disorders. 11 In the current study, the contribution of AZA in the pathogenesis of cutaneous manifestations was supported by the diagnostic criteria proposed by Walker and Cohen. 11 For instance, in case 1, the possibility of infection was denied by blood culture, pathological findings and clinical course showing no improvement even after the administration of antibiotics.…”

Section: Discussionsupporting

confidence: 71%

“…11 In the current study, the contribution of AZA in the pathogenesis of cutaneous manifestations was supported by the diagnostic criteria proposed by Walker and Cohen. 11 For instance, in case 1, the possibility of infection was denied by blood culture, pathological findings and clinical course showing no improvement even after the administration of antibiotics. The patient had taken no medication that is known to trigger neutrophilic dermatosis.…”

Section: Discussionsupporting

confidence: 71%

“…Systemic cutaneous reactions were closely associated with hyperactivation of neutrophils and were mostly treated with systemic interventions including corticosteroid administration. The recent retrospective analysis of 83 cases of Sweet syndrome elucidated that 44%, 24% and 2% of the cases were categorized as the malignancy‐associated form, the drug‐induced form in the setting of malignancy and the drug‐induced form, respectively. MDS was the second most common causative malignancy after acute myeloblastic leukemia, further highlighting the necessity of excluding the possibility of MDS‐associated neutrophilic disorders .…”

Section: Discussionmentioning

confidence: 99%

“…The recent retrospective analysis of 83 cases of Sweet syndrome elucidated that 44%, 24% and 2% of the cases were categorized as the malignancy‐associated form, the drug‐induced form in the setting of malignancy and the drug‐induced form, respectively. MDS was the second most common causative malignancy after acute myeloblastic leukemia, further highlighting the necessity of excluding the possibility of MDS‐associated neutrophilic disorders . In the current study, the contribution of AZA in the pathogenesis of cutaneous manifestations was supported by the diagnostic criteria proposed by Walker and Cohen .…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Cutaneous adverse events induced by azacitidine in myelodysplastic syndrome patients: Case reports and a lesson from published work review

Shimoda‐Komatsu

Mizukawa

Takayama

et al. 2020

The Journal of Dermatology

View full text Add to dashboard Cite

Subcutaneous injection of azacitidine (AZA) is an important treatment option for myelodysplastic syndrome (MDS), which improves overall survival. In hematology, the incidence of AZA‐induced cutaneous adverse events (AE) has been known to be relatively high, which has not been well recognized by dermatologists. Discontinuation of AZA can result in the deterioration of MDS disease activity. Therefore, on dermatological consultation, precise evaluation of AE severity and careful consideration is required for post‐AE medication management. To enhance our understanding of AZA‐induced cutaneous AE, we report four cases with two representative cutaneous AE subtypes and summarize the clinicopathological phenotypes and courses of the cases in the published work. Case 1, a 71‐year‐old man, developed neutrophilic dermatosis involving the dermis and subcutaneous tissue. The other three cases, a 75‐year‐old man, a 78‐year‐old woman and a 68‐year‐old man, presented injection‐site erythema associated with flare‐up reaction. Discontinuation of AZA was necessary for case 1 alone. The published work review delineated three major subtypes of AZA‐induced cutaneous AE: systemic cutaneous reaction, neutrophilic dermatosis type and erythematous type injection‐site reaction. Histologically, the first two subtypes are mostly characterized by neutrophil infiltration, while the third subtype presents lymphocytic cell infiltration. Neither AZA discontinuation nor intensive interventions were required for the erythematous type injection‐site reaction, while AZA termination or systemic treatments, represented by corticosteroid administration, were preferentially conducted for the systemic cutaneous reaction or the neutrophilic dermatosis type injection‐site reaction subgroup. These observations support the necessity of subtype‐dependent treatment strategies for the management of AZA‐induced cutaneous AE.

show abstract

Ulcerated Plaques on the Scalp and Dorsal Hands of an Older Man

Goyal

O’Leary

Rosenbach

2022

JAMA

Self Cite

View full text Add to dashboard Cite

Sweet syndrome in patients with and without malignancy: A retrospective analysis of 83 patients from a tertiary academic referral center

Cited by 77 publications

References 28 publications

Insights Into the Characteristics of Sweet Syndrome in Patients With and Without Hematologic Malignancy

Insights Into the Characteristics of Sweet Syndrome in Patients With and Without Hematologic Malignancy

Cutaneous adverse events induced by azacitidine in myelodysplastic syndrome patients: Case reports and a lesson from published work review

Ulcerated Plaques on the Scalp and Dorsal Hands of an Older Man

Contact Info

Product

Resources

About